GSK 2033
GSK 2033 性质
| 储存条件 | 2-8°C |
|---|---|
| 溶解度 | DMF:5.0(最大浓度 mg/mL);8.45(最大浓度 mM) DMSO:17.46(最大浓度 mg/mL);29.51(最大浓度 mM) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| InChIKey | PSOXOVKYGWBTPB-UHFFFAOYSA-N |
| SMILES | CS(C1=CC=CC(C2=CC=C(CN(S(C3=C(C)C=C(C)C=C3C)(=O)=O)CC4=CC=C(C(F)(F)F)O4)C=C2)=C1)(=O)=O |
GSK 2033 用途与合成方法
pIC50: 7 (LXRα), 7.4 (LXRβ)
GSK2033 is a LXR antagonist with pIC 50 s of 7 and 7.4 for LXRα or LXRβ, respectively. GSK2033 dose-dependently suppresses basal transcription in full-length LXRα or full-length LXRβ cotransfection assays with IC 50 s of 17 nM and 9 nM, respectively. GSK2033 also effectively suppresses the transcription of an ABCA1 driven luciferase reporter dose-dependently displaying IC 50 s of 52 nM for LXRα and 10 nM for LXRβ. GSK2033 also suppresses the expression of both of fatty acid synthase ( FASN ) and SREBP1 .
One month treatment of GSK2033 does not have significant effects on hepatic triglyceride levels. Plasma triglyceride levels are also unaffected by treatment with GSK2033.
GSK 2033 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-108688 | 1221277-90-2 | 1 mg | 457 | |
| 2026-09-15 | HY-108688 | 1221277-90-2 | 1221277-90-2 | 5mg | 1100 |
